
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type from the provided ranked marker list, we will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **GDF15**: Growth differentiation factor 15, involved in stress response and inflammation.<br>- **HSPA2**: Heat shock protein family A (Hsp70) member 2, involved in protein folding and stress response.<br>- **S100A6**: S100 calcium-binding protein A6, involved in cell cycle progression and differentiation.<br>- **CXCL14**: Chemokine (C-X-C motif) ligand 14, involved in immune response and cell migration.<br>- **AREG**: Amphiregulin, a growth factor involved in cell proliferation and differentiation.<br>- **GATA3**: A transcription factor involved in cell differentiation, particularly in epithelial cells.<br><br>### Step 2: List the Key Cell Type Markers<br>- **SCGB2A2**: Secretoglobin family 2A member 2, a marker for mammary gland epithelial cells.<br>- **KRT19, KRT18, KRT8**: Keratins, markers for epithelial cells, particularly luminal epithelial cells in the breast.<br>- **TFF3**: Trefoil factor 3, associated with mucosal protection and repair, often expressed in epithelial cells.<br>- **CLDN7**: Claudin 7, a component of tight junctions in epithelial cells.<br>- **GATA3**: Also a marker for luminal epithelial cells in the breast.<br>- **ANKRD30A**: Ankrd30a, associated with breast tissue, particularly luminal epithelial cells.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas and literature on breast tissue scRNA-seq, the markers SCGB2A2, KRT19, KRT18, KRT8, and GATA3 are strongly associated with luminal epithelial cells in the breast. These markers are commonly used to identify luminal subtypes in breast cancer studies.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of markers such as SCGB2A2, KRT19, KRT18, KRT8, and GATA3, the most probable general cell type is **epithelial cells**, specifically luminal epithelial cells.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Luminal Epithelial Cells**: The presence of SCGB2A2, KRT19, KRT18, KRT8, and GATA3 strongly suggests luminal epithelial cells, which are a major component of breast tissue and often involved in breast cancer.<br>2. **Luminal Progenitor Cells**: These cells express similar markers to mature luminal cells but may also express markers like ANKRD30A, indicating a progenitor state.<br>3. **Basal-like Epithelial Cells**: Although less likely due to the dominance of luminal markers, basal-like cells can sometimes express overlapping keratins, but the lack of specific basal markers makes this less probable.<br><br>The most likely subtype based on the markers is **Luminal Epithelial Cells**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset indicates that the cell cluster is most likely composed of luminal epithelial cells. This conclusion is supported by the expression of key markers such as SCGB2A2, KRT19, KRT18, KRT8, and GATA3, which are well-documented markers for luminal epithelial cells in the breast. These cells are crucial in the context of breast cancer, as they are often the origin of luminal subtype breast cancers.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**: <br>   - The key functional markers (GDF15, HSPA2, S100A6, CXCL14, AREG, GATA3) and key cell type markers (SCGB2A2, KRT19, KRT18, KRT8, TFF3, CLDN7, GATA3, ANKRD30A) are all present in the provided marker list.<br>   - The markers used to identify the cell type as luminal epithelial cells (SCGB2A2, KRT19, KRT18, KRT8, GATA3) are consistent with known markers for this cell type.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The analysis does not strongly suggest the presence of multiple distinct cell types. The markers predominantly support the identification of luminal epithelial cells, with a potential minor presence of luminal progenitor cells, which is reasonable given the context of breast tissue.<br><br>The annotation process has been thorough, using a well-documented set of markers to identify luminal epithelial cells, which aligns with the context of breast tissue analysis. No further investigation into mixed cell types is necessary based on the current evidence.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Epithelial Cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Luminal Epithelial Cells</li><li>Luminal Progenitor Cells</li><li>Basal-like Epithelial Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">85</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the markers associated with luminal epithelial cells in the context of human breast cancer. The analysis correctly identifies key markers such as SCGB2A2, KRT19, KRT18, KRT8, and GATA3, which are well-documented indicators of luminal epithelial cells. This is a significant strength, as these markers are crucial for identifying the luminal subtype in breast cancer studies.<br><br>The annotation process also shows a balanced consideration of both functional and cell type-specific markers. For instance, the inclusion of functional markers like GDF15 and HSPA2, alongside cell type markers, provides a comprehensive view of the cell population's characteristics. This balance is essential for a nuanced understanding of the data.<br><br>However, there are a few areas where the analysis could be improved. While the annotation does consider the possibility of luminal progenitor cells, it does not delve deeply into the potential presence of basal-like epithelial cells, despite mentioning them. Although the markers predominantly support luminal epithelial cells, a more detailed exploration of the basal-like possibility could enhance the analysis, especially given the complexity of breast cancer cell populations.<br><br>Additionally, the annotation does not explicitly address the rank of the markers, which could be important in determining the primary cell type. For example, if SCGB2A2 or GATA3 appeared earlier in the list, it might further strengthen the conclusion of luminal epithelial cells as the main cell type.<br><br>Overall, the annotation is scientifically accurate and provides a comprehensive view of the cell types present, with a strong focus on luminal epithelial cells. The analysis is thorough and well-supported by the marker data, but a deeper exploration of potential mixed cell types and consideration of marker rank could improve the results.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    